Omega-3 (EPA/DHA) — ingrediens

Q: What dose of Omega-3 (EPA/DHA) should I take?

The trial dose in published human studies is 2000 mg per day, with a range of 1000 to 4000 mg per day. Always consult a qualified clinician before starting any supplement.

Q: What is the best Omega-3 (EPA/DHA) supplement?

We track 42 products containing Omega-3 (EPA/DHA). The top-ranked product scores 9.2 out of 10 on our composite scale. See the comparison table above.

Q: What is the evidence grade for Omega-3 (EPA/DHA)?

Omega-3 (EPA/DHA) has evidence grade A, meaning it is well-supported by replicated human trials.

Short answer

Omega-3 (EPA/DHA) (Omega-3 Fatty Acids (EPA + DHA)) is a foundational with evidence grade A, meaning it is well-supported by replicated human trials. We track 42 produkter containing Omega-3 (EPA/DHA). Typical doses range from 1105.0 to 2150.0 mg per portion. The top-ranked product scores 9.2 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $57.00 per månad.

Bevisning grade: A Produkter in database: 42 Kategori: Foundational

Top Omega-3 (EPA/DHA) produkter

Product	Dose	Pris/mo	3rd-party tested	Poäng
Omega-3 Fish Oil	1900.0 mg	$39.99	Yes	9.2
Triple Strength Omega-3 Fish Oil	2070.0 mg	$55.99	Yes	9.1
Ultimate Omega-D3 2X	2150.0 mg	$55.95	Yes	8.6
O3 Ultra Pure Fish Oil	1750.0 mg	$57.00	Yes	8.6
Lion Heart Pure Omega 3	1730.0 mg	$40.00	Yes	8.6

Scores are editorial judgments, not a scientific standard. Se how we score.

What it is

Two specific fats found in oily fish (salmon, sardines, mackerel) and algae. Your body needs them but can't make them well from plant sources.

Why people take it

Meta-analyses of tens of thousands of participants show cardiovascular event reductions. The recent VITAL and REDUCE-IT trials clarified who benefits (people with high triglycerides, existing heart risk, or low omega-3 intake). Brain, eye, and inflammation benefits also well-documented.

Our verdict

If you can only pick one supplement for longevity, omega-3 is a strong candidate, especially if you don't eat fatty fish 2× a week.

Structure & class

EPA (eicosapentaenoic acid, 20:5 n-3) and DHA (docosahexaenoic acid, 22:6 n-3). Long-chain PUFAs.

Mechanism & clinical data

REDUCE-IT (2019) demonstrated 25% MACE reduction at 4 g EPA (icosapent ethyl) in high-risk patients. Meta-analyses confirm triglyceride and blood-pressure lowering. Omega-3 index target: 8 to 12%.

Pharmacokinetics

Days (incorporation into cell membranes).

Dose & forms

Trial dose

2000 mg

/ day

Range in trials

1000 to 4000 mg

/ day

Common forms

Triglyceride form (TG), Ethyl ester (EE), Phospholipid (krill), Algal (vegan)

What to watch out for

Ethyl ester (cheaper) absorbs worse than triglyceride form unless taken with fatty meal. Check third-party oxidation testing (TOTOX <10).

Säkerhet limits and interactions

When a product exceeds the UL or contains an ingredient with clinically significant interactions, a "Review advised" flag appears on its product page and links here.

Known drug interactions

High doses (2-15 g/day) may increase bleeding time; caution with anticoagulants/antiplatelet drugs.

Säkerhet note

IOM has not set a formal UL; FDA advises supplement labels not to recommend more than 2 g/day EPA+DHA. Higher doses (≥1 g/day, more pronounced at 1.8-4 g/day) show a dose-dependent increase in atrial fibrillation risk in trials such as REDUCE-IT and STRENGTH.

Source: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/

Where this dose comes from

The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.

When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.

Regelverk status

EUFood supplement, health claims authorised

USDietary supplement + Rx (Vascepa/Lovaza)

UKFood supplement

CANHP + Rx

Timeline

Regelverk events, evidence grade changes, and key research milestones for Omega-3 (EPA/DHA), most recent first. Every entry links to its primär source.

2026 Research milestone

Abuknesha & Harris 2026 (Circulation: Arrhythmia)

Largest metaanalys to date (35 RCTs, 114,592 participants). Omega-3 doses below 1,500 mg/day do not increase atrial fibrillation risk. Only prescription doses above 1,500 mg/day showed 0.8% absolute risk increase.

Source →
2026 Research milestone

Lok et al. 2026 PISCES Trial (NEJM)

Large international RCT in hemodialysis patients found fish oil supplementation reduced cardiovascular events by 43% compared to placebo.

Source →
2026 Research milestone

Norouzzadeh et al. 2026 (J Am Nutr Assoc)

Meta-analysis found omega-3 supplementation significantly improved vascular health biomarkers including flow-mediated dilation and arterial stiffness.

Source →
2025-04 Regelverk single source

EU Court sharpens the bar for botanical health claims

A Court of Justice of the European Union ruling in april 2025 further tightened the requirements for how botanical ingredients (herbs, plant extracts) can be marketed with health claims in the EU, effectively removing much of the flexibility of the on-hold list.
2024-06 Regelverk confirmed

EU report identifies 117 supplement substances as potential health risks

The HoA Working Group on Food Supplements (26 European countries) published its first report evaluating 117 substances used in food supplements. Of these, 65 were assessed as likely novel foods, 6 were already regulated, 34 had insufficient data, and 12 were prioritized for Article 8 restriction under Regulation (EC) No 1925/2006. The 12 priority substances include ashwagandha, curcumin, melatonin, piperine, St. John's wort, coumarin, p-synephrine, maca, holy basil, Melaleuca, black cohosh, and L-tryptophan. The report drew on 1,500 RASFF alerts reviewed between 2017 and mid-2022.

Source →
2024 Research milestone

HoA 2024 (BVL/NVWA, EU)

26-country EU working group prioritized curcumin for Article 8 restriction. Flagged for possible carcinogenic, mutagenic, or reprotoxic properties at supplement doses exceeding normal dietary intake.

Source →
2023 Research milestone

Barbaresko et al. 2023 (cognitive review)

Review of RCTs found that 3.36 g/day EPA+DHA slowed cognitive aging by 2.5 years in cognitively healthy people with coronary artery disease, with more mixed results in general older populations.

Source →
2021 Research milestone

Khan et al. 2021 (38 RCTs metaanalys)

A metaanalys of 38 RCTs (149,051 participants) found omega-3 fatty acids reduced cardiovascular mortality, non-fatal MI, and major adverse cardiovascular events, with greater benefit from EPA monotherapy than EPA+DHA.

Source →
2021 Research milestone

Bernasconi et al. 2021 (Mayo Clin Proc)

Across 40 RCTs (135,267 participants), EPA/DHA supplementation reduced risk of myocardial infarction and coronary heart disease events in a dose-dependent manner.

Source →
2019-06 Regelverk confirmed

FDA adds qualified health claims for EPA/DHA and blood pressure

The FDA announced it would not object to qualified health claims stating that consuming EPA and DHA combined may reduce blood pressure and the risk of hypertension, a risk factor for coronary heart disease. The agency found some credible evidence but concluded it was inconsistent and inconclusive. Produkter bearing the claim must contain at least 0.8 g EPA+DHA per portion. The FDA also raised the safe upper intake limit from 3 g/day to 5 g/day for supplements using the claim.

Source →
2019 Research milestone

REDUCE-IT 2019 (NEJM)

In 8,179 statin-treated patients with elevated triglycerides, icosapent ethyl (EPA) reduced major cardiovascular events by 25% versus placebo over a median 4.9 years.

Source →
2019 Research milestone

VITAL Trial 2019 (N=25,871)

In 25,871 U.S. adults followed 5.3 years, daily marine omega-3 (1g) supplementation did not significantly reduce major cardiovascular events or total cancer incidence in the general population.

Source →
2012 Regelverk confirmed

EU authorises health claims for DHA and EPA

Regulation (EU) 432/2012 established a list of authorised health claims for DHA and EPA, including contributions to normal brain function (250 mg/day DHA), normal vision (250 mg/day DHA), normal heart function (250 mg/day EPA+DHA), maintenance of normal blood triglyceride levels (2 g/day EPA+DHA), and maintenance of normal blood pressure (3 g/day EPA+DHA). Produkter must contain at least 40 mg EPA+DHA per 100 g and per 100 kcal to bear the source claim.

Source →
2006-12 Regelverk confirmed

EU Health Claims Regulation adopted

Regulation (EC) No 1924/2006 laid down harmonised rules for nutrition and health claims made on foods, including supplements. Only claims listed in the EU Register of authorised claims can be used. Rejected botanical claims are held in a separate on-hold list.

Source →
2004 Regelverk confirmed

FDA allows first qualified health claim for EPA/DHA omega-3 and heart disease

The FDA permitted a qualified health claim stating that supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. This was the first time the FDA allowed a heart-related claim for omega-3 supplements, though with qualifying language acknowledging the evidence was not definitive.

Source →
1997 Regelverk confirmed

EU introduces the Novel Food Regulation

Regulation (EC) No 258/97 required any food or food ingredient without a history of consumption in the EU before 15 maj 1997 to be authorised before being placed on the market. This is the framework that captures NMN, spermidine as a supplement ingredient, urolithin A, and many other longevity actives.

Source →

Tolerability data

Reported adverse events

Consumer reports submitted to an official government adverse-event database. These reports mention this ingredient but do not prove it caused the reaction. Report volume reflects market penetration as much as inherent risk.

1,054

total reports

High report volume

Dyspnoea

103

Nausea

102

Diarrhoea

99

Choking

88

Vomiting

83

Hypersensitivity

68

Dizziness

66

Pruritus

64

Data source

Retrieved from the FDA Adverse Event Reporting System (CAERS) via the openFDA API. Verified 2026-08-06. Reports are voluntary consumer submissions and mandatory serious-event filings. They establish surveillance, not causality.

2026 evidence refresh

Omega-3 fish oil (EPA and DHA) lowers triglycerides and modestly cuts cardiovascular events, with effects varying sharply by formulation and dose.

Verified 2026-07-19. We update this section as new peer-reviewed trials land.

Human RCT base

80+

peer-reviewed randomised trials

Largest single trial

n = 25871

VITAL trial found no significant reduction in the primär composite cardiovascular endpoint, but did find a reduced risk of myocardial infarction as a secondary endpoint, especially among participants with low fish intake. source

Best-supported claim

The strongest human evidence is for cardiovascular risk reduction, but it depends heavily on formulation. REDUCE-IT, using 4 g/day of purified EPA (icosapent ethyl), cut the composite cardiovascular endpoint by 25% (https://www.sciencedirect.com/science/article/abs/pii/S0025619619304112). A 2021 metaanalys of 13 RCTs and 127,477 participants found marine omega-3 significantly reduced myocardial infarction, coronary heart disease death, total CHD, CVD death, and total CVD, with effects strengthened once REDUCE-IT was included (https://www.ahajournals.org/doi/10.1161/JAHA.119.013543). A separate 2021 metaanalys of 38 RCTs and 149,051 participants found EPA-only therapy produced a larger cardiovascular mortality reduction (RR 0.82) than EPA plus DHA combinations (RR 0.94), suggesting EPA alone may be the more potent cardioprotective form (https://pmc.ncbi.nlm.nih.gov/articles/PMC8413259/).

Not supported by the evidence base

Marketers sell omega-3 broadly as a general life-extension and all-cause mortality supplement, but the highest-quality evidence does not support this. The 2018 Cochrane review, the most rigorous synthesis available, pooled 79 RCTs and 112,059 participants and found little or no effect of long-chain omega-3 on all-cause mortality (RR 0.98) or cardiovascular mortality, rated as high-quality evidence (https://pubmed.ncbi.nlm.nih.gov/30019766/). A 2022 dose-related metaanalys of 19 RCTs and 97,709 participants likewise found no statistically significant reduction in all-cause, cardiac, or stroke mortality at any studied dose (https://www.sciencedirect.com/science/article/abs/pii/S0261561422000735). For brain health, DHA supplementation shows benefit only in mild cognitive impairment, not in diagnosed Alzheimer's disease, per a review of RCT evidence (https://pubmed.ncbi.nlm.nih.gov/36637075/).

Typical dose

1 to 4 g/day combined EPA/DHA, with higher doses (2-4 g/day, EPA-predominant) used for triglyceride and cardiovascular-event reduction

Säkerhet

Omega-3 supplements are generally well tolerated at typical doses. The main documented risk is bleeding and, at high doses of purified EPA, atrial fibrillation. The 2021 metaanalys of 38 RCTs found increased AF risk with omega-3 supplementation, a known tradeoff against its cardiovascular mortality benefit (https://pmc.ncbi.nlm.nih.gov/articles/PMC8413259/). Fishy aftertaste and mild GI upset are common with lower-quality formulations. Choose produkter tested for oxidation and heavy metals.

Interactions worth flagging

blood thinners
antiplatelet drugs
blood pressure medications

Three recent studies to know

Marine Omega-3 Supplementation and Cardiovascular Disease: An Uppdaterad Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Deltagare

Tidskrift of the American Heart Association 2021 · n =

Läs studie →
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematisk översikt and metaanalys

PMC (peer-reviewed cardiovascular journal) 2021 · n =

Läs studie →
Omega-3 fatty acids for the primär and secondary prevention of cardiovascular disease

Cochrane Database of Systematic Reviews 2018 · n =

Läs studie →

Landmark studies

REDUCE-IT 2019 (NEJM)

In 8,179 statin-treated patients with elevated triglycerides, icosapent ethyl (EPA) reduced major cardiovascular events by 25% versus placebo over a median 4.9 years.
Läs studie →
VITAL Trial 2019 (N=25,871)

In 25,871 U.S. adults followed 5.3 years, daily marine omega-3 (1g) supplementation did not significantly reduce major cardiovascular events or total cancer incidence in the general population.
Läs studie →
Khan et al. 2021 (38 RCTs metaanalys)

A metaanalys of 38 RCTs (149,051 participants) found omega-3 fatty acids reduced cardiovascular mortality, non-fatal MI, and major adverse cardiovascular events, with greater benefit from EPA monotherapy than EPA+DHA.
Läs studie →
Bernasconi et al. 2021 (Mayo Clin Proc)

Across 40 RCTs (135,267 participants), EPA/DHA supplementation reduced risk of myocardial infarction and coronary heart disease events in a dose-dependent manner.
Läs studie →
Barbaresko et al. 2023 (cognitive review)

Review of RCTs found that 3.36 g/day EPA+DHA slowed cognitive aging by 2.5 years in cognitively healthy people with coronary artery disease, with more mixed results in general older populations.
Läs studie →
HoA 2024 (BVL/NVWA, EU)

26-country EU working group prioritized curcumin for Article 8 restriction. Flagged for possible carcinogenic, mutagenic, or reprotoxic properties at supplement doses exceeding normal dietary intake.
Läs studie →
Abuknesha & Harris 2026 (Circulation: Arrhythmia)

Largest metaanalys to date (35 RCTs, 114,592 participants). Omega-3 doses below 1,500 mg/day do not increase atrial fibrillation risk. Only prescription doses above 1,500 mg/day showed 0.8% absolute risk increase.
Läs studie →
Lok et al. 2026 PISCES Trial (NEJM)

Large international RCT in hemodialysis patients found fish oil supplementation reduced cardiovascular events by 43% compared to placebo.
Läs studie →
Norouzzadeh et al. 2026 (J Am Nutr Assoc)

Meta-analysis found omega-3 supplementation significantly improved vascular health biomarkers including flow-mediated dilation and arterial stiffness.
Läs studie →

Found in these produkter (42)

Alla produkter in our catalog that contain Omega-3 (EPA/DHA), ranked by our overall score. Ranking is editorial, never paid.

Transparent Labs

Omega-3 (EPA/DHA) · Omega-3 Fatty Acids (EPA + DHA)